摘要
【目的】探讨血清肿瘤特异性生长因子(TSGF)测定在骨肉瘤患者新辅助化疗中的作用和意义。【方法】监测74例骨肉瘤患者新辅助化疗前、后1个月、3个月、6个月血清TSGF含量的变化,并结合临床疗效综合分析TSGF变化与疗效的关系。【结果】经过新辅助化疗后,治疗有效的患者血清中TSGF水平较治疗前有明显下降,而病情恶化的患者血清中TSGF水平逐渐升高。【结论】动态测定血清TSGF含量对骨肉瘤患者的病情监测、新辅助化疗疗效观察及预后具有重要的意义,TSGF可作为一项具有参考价值的肿瘤标志物。
[Objective]To explore the significance of tumor specific growth factor （TSGF） determination in curative effects for osteosarcoma following the neoadjuvant chemotherapy. [Methods]The serum levels of TSGF were monitored in 74 cases with osteosarcoma prior to the therapy and one month, three months, six months after the neoadjuvant chemotherapy. [Results]After the treatments ,the serum levels of TSGF in the groups of CR and PR decreased, but increased gradually in PD group. [Conclusion]It is of great value to monitor TSGF in curative effects for osteosarcoma after the neoadjuvant chemoeherapy with good sensitivity ,speciality and accuracy.
出处
《医学临床研究》
CAS
2006年第7期1024-1025,共2页
Journal of Clinical Research
